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In this issue of AJHG, Alarco´n et al.,1 Arking et al.,2 and Bakkaloglu et al.3 identify a series of functional variants in the CNTNAP2 gene
that unequivocally implicate this gene as causing Type 1 autism in the general population.Autism Spectrum Disorder (ASD) is
a catch-all diagnosis for a set of poorly
understood neurodevelopmental dis-
orders that are clinically heteroge-
neous, with a spectrum of severity,
characterized by repetitive self-stimu-
latory behaviors and communication
and socialization deﬁcits. ASD is tradi-
tionally diagnosed by the age of 3
years and the severe forms can be
accompanied by language regression,
seizures, and low measured IQ. The
more strict diagnosis of ‘‘autism’’ is
made through behavioral testing on
the ADOS and/or ADI-R rating sys-
tems. The umbrella diagnosis of ASD
is approaching 1% of all births, likely
through a combination of ascertain-
ment bias and increased population
exposure to unknown environmental
risk factors or mutagens. Epidemio-
logic studies of ASD have failed to
identify deﬁnitive evidence of expo-
sures correlating to increased risk of
the disorder. It will be critical to dis-
sect the genetic subclasses of ASD
prior to embarking on a new wave of
epidemiology to identify environ-
mental risk factors, because it is
reasonable to assume that individual
environmental exposures act differ-
ently on each genetic subclass of the
disorder.
Twin studies (both with strictly de-
ﬁned autism and the broader ASD
phenotype) as well as familial cluster-
ing indicate a strong genetic compo-
nent to predisposition. The clinical
heterogeneity of this disorder will
likely be explained in large part by
genetic heterogeneity; a multitude of
linkage studies (including the large
multinational Autism Genome Pro-ject) have reproducibly identiﬁed sev-
eral loci by studying ASD phenotypes
segregating through rare pedigrees
with multiple affecteds.4 Because the
more common forms of ASD are spo-
radic and ASD individuals are less
likely to reproduce, we can assume
that this majority of ASD predisposi-
tion is caused by either SNP variants
segregating through the population
or by a high newmutation rate in pre-
disposition genes.
Until recently, there existed only
three genes with limited evidence
(often only in a few probands) impli-
cating them as causative of ADOS/
ADI-R-deﬁned autism, when mutated.
Mutations of the SH3 and multiple
ankyrin repeat domains 3 (SHANK3)
gene have recently been reported to
be associated with ASD in a small
number of individuals, and mutations
in this gene have been found in less
than 1% of probands tested.5,6
SHANK3 codes for an adaptor protein
in the postsynaptic density of the
excitatory neuron and likely plays
a role in the functional and structural
organization of the dendritic spine
and the synapse. Mutations in a sec-
ond gene, neuroligin-3 (NLGN3),
have been shown to cause ASD when
mutated, but have not been replicated
widely, and there are reports of lack of
replication.7,8 Finally, the contactin
associated protein-like 2 (CNTNAP2)
gene at 7q35, a member of the neu-
rexin superfamily, was described by
our group in 2006 to cause severe
autism with medication-insensitive
temporal lobe seizures, language re-
gression, and low IQ when the car-
boxy terminal of the protein productThe American Journalwas truncated through a homozygous
loss-of-function mutation in a single
family.9 The mechanism of action of
the mutation is likely altered attach-
ment of the axon to the glia via the
TAG-1 protein and mislocalization of
ion channels at the juxtaparanodal
junction leading to cortical dysplasia.
This ﬁnding is now replicated in
a large sampling of the autism popula-
tion by three groups in this issue of
AJHG and places the CNTNAP2 gene
as the ﬁrst widely replicated autism-
predisposition gene. Alarco´n et al.,1
Arking et al.,2 and Bakkaloglu et al.3
all describe functional variants (both
common and rare) that predispose to
autism in the general population. It
is reasonable at this point to deﬁne
CNTNAP2 mutation-positive autistic
cases as having ‘‘Type 1 autism.’’
Bakkaloglu and colleagues3 report
a de novo 7q35 inversion that dis-
rupts CNTNAP2 between exons 10
and 13 in a child with autistic fea-
tures. This evidence led them to rese-
quence all 24 exons of the gene in
635 affecteds and 942 controls. Thir-
teen rare variants were identiﬁed in
cases, and of these eight were pre-
dicted to have negative consequences
on gene function because they oc-
curred in evolutionarily conserved re-
gions of the gene. Although predicted
deleterious variants were also found in
the control cohort, there were roughly
twice as many variants found in the
cases. One predicted deleterious vari-
ant (I869T) was found to be present
in four affected individuals from three
different families, but not present in
>4000chromosomes fromunaffecteds.
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event that likely leads toASDinasingle
individual and characterizes a series
of rare variants in probands that are
predicted to have functional conse-
quences on gene function.
Alarco´n et al.1 also replicate the
CNTNAP2 locus as causative of au-
tism. Predicated on their previous
work identifying a 10 cM linkage
peak at 7q35 in families with language
deﬁcits and ASD, the authors geno-
typed 172 parent-child trios at 2758
SNPs across the linkage peak and nar-
rowed the region to 4 genes (5 haplo-
type blocks), including CNTNAP2.
Eight SNPs covering these 5 loci
were genotyped in an independent
304 ASD families, and only SNP
rs2710102, which is in CNTNAP2, re-
mained signiﬁcant, and only in male
probands. The signiﬁcant association
was speciﬁcally with ‘‘age of ﬁrst
word’’ in the ASD probands. The au-
thors go on to describe a microdele-
tion in the gene that is carried by
a proband and his father, but never
seen in 1000 control chromosomes.
A common SNP variant (rs7794745)
within the CNTNAP2 gene was identi-
ﬁed by Arking and colleagues2 under
the established 7q35 linkage peak by
association mapping with strictly de-
ﬁned autism cases, and conﬁrmed in
an independent replication popula-
tion (with broader diagnostic inclu-
sion criteria) as enriched (‘‘T’’ allele)
in probands with autism. Of particular
interest is that the T allele is more
strongly associated with the pheno-
type when inherited from the mother,
although studies examining parent-
of-origin imprinting at this locus
have yet to be done. The ﬁnding that
a common variant is associated with
increased risk of autismwasmade pos-
sible by careful clinical assessment
and reduction of clinical heterogene-
ity to the greatest extent possible fol-
lowed by focused association analysis
within a linkage region, which al-
lowed this subtle association to be
detected without genome-wide back-
ground noise.
These three publications reiterate
the point that rare monogenic forms
of common complex genetic disorders
yield critical insight into disease pro-8 The American Journal of Human Genetics 8cesses, and these studies should con-
tinue to be carefully evaluated in com-
bination with careful phenotyping of
‘‘sporadic’’ disease and recent whole-
genome association approaches. To
address the overarching hypothesis
that common variants predispose to
any subtype or all ASD, a series of
whole-genome association studies at
high SNP density have been per-
formed. The largest of these data sets
was generated on more than 3000
probands and family members with
approximately 500,000 SNPs and
deposited into the Autism Genetic
Resource Exchange (AGRE) database
for public access. Preliminary analysis
of this elegant data set indicates that
extremely signiﬁcant p values that
exceed multiple testing correction
are not present. This is possibly due
to the clinical and genetic heterogene-
ity that we know exists within ASD. It
is reasonable to think, based on the
three studies presented herein, that
a priori phenotypic stratiﬁcation or
linkage positivity to a certain locus
will enhance the ability to detect asso-
ciations between common variants
and these subgroups.
The three studies herein1–3 have
moderate sample overlap and use
different strategies to narrow the
phenotype of the ASD cohorts to rela-
tive homogeneity before performing
genotyping/resequencing across the
CNTNAP2 gene locus. Nevertheless,
the three studies together identify
a set of common and rare variants
that provide unequivocal evidence
that the CNTNAP2 gene, when disrup-
ted, leads to a subtype of ASD. This
genetic subtype can be clinically char-
acterized by ADOS/ADI-R-deﬁned
autism with language deﬁcits and
potential gender bias and parent-of-
origin effects. Type 1 autism may
also be associated with seizures. It
will be important to begin to charac-
terize the genotype-phenotype corre-
lations across this gene so that we
may begin to use the CNTNAP2 as a
diagnostic and prognostic tool. This
gene is a very large target (~2.3 Mb ge-
nomic locus) for mutations. ASD indi-
viduals have reduced reproduction
and thus it is reasonable to assume2, 7–9, January 2008a high new mutation rate in this
gene. Now that we have deﬁnitive evi-
dence from several perspectives that
integrity of the neuroligin-neurexin
axis is critical fornormaldevelopment,
wemust launch into a candidate gene-
resequencing effort to fully describe
mutations in the other members of
these gene families in ASD. Finally,
our collaborative group has been able
to identify individuals from our initial
family who carry the homozygous
loss-of-function mutation that we
originally described in 2006. Several
of these children were given the anti-
seizure medication valproic acid prior
to onset of symptoms in an attempt
to control seizures and other aspects
of the disorder, and the preliminary
results are promising (K. Strauss, per-
sonal communication). These prelimi-
nary ﬁndings lead one to speculate
whether early detection of CNTNAP2
mutation carriers coupled with early
intervention could coax children
through a critical period in develop-
ment (12–24months of age) and allow
them to emerge undamaged and con-
tinue to develop normally thereafter.
The modern technologies and strate-
gies derived from the Human Genome
Project, coupled with the elegant sam-
ple banking, phenotyping, and data
dissemination resources of groups like
AGRE, are resulting, ﬁnally, in the un-
raveling of Autism Spectrum Disorder.
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